Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome.
about
Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisIntravenous immunoglobulin for Guillain-Barré syndromeIntravenous immunoglobulin for Guillain-Barré syndromeGuillain–Barré syndrome in Colombia: where do we stand now?Intravenous immunoglobulin and Alzheimer's disease: what now?Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Plasma exchange as a cost-effective option for treating Guillain-Barré syndrome.Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosisHospital Admissions, Transfers and Costs of Guillain-Barré Syndrome.Pattern of intravenous immunoglobulins (IVIG) use in a pediatric intensive care facility in a resource limited setting.Therapeutic apheresis for patients with cancer.Use of Polyclonal Intravenous Immunoglobulin at a Paediatric Referral Hospital in South Africa Between 2009 and 2012.Efficacy and Factors Associated with Treatment Response of Intravenous Immunoglobulin in Inpatients with Refractory Inflammatory Bowel Diseases.Safety of intravenous immunoglobulin and plasma exchange in critically ill patients.Daily plasma exchange in severe Guillain-Barré syndrome helps in early weaning from ventilator: A lesson from a case.Gamunex® in Guillain-Barré Syndrome: A Postmarketing, Retrospective, Observational Study.Beneficial effect of a multimerized immunoglobulin Fc in an animal model of inflammatory neuropathy (experimental autoimmune neuritis).Treatment of MuSK-Associated Myasthenia Gravis.
P2860
Q22251013-194FEBE8-9BED-4D57-9E61-D5CF2A2FA6DAQ24193522-DFC62E2E-7D02-4903-AF4D-9901D9AD53B3Q24202100-57A84861-3939-4A29-963B-8BA817CC94F4Q26252481-5CE1ABB1-A583-4D76-8BF7-E66F3F90F622Q27000371-5CAB607D-D8ED-4BA7-B538-08B7B89ED628Q30276550-C4A91ADA-A86D-43F4-A1EE-48A63A75BE96Q33589929-17726429-9A97-420D-9659-2D1084FF33BDQ35231795-4398BD3D-E304-41B4-BA20-D0C4860E2512Q35918443-9E08D90A-45B3-47CE-81BF-7688E9564672Q38162842-846E5AD9-F94B-4096-8A8E-1E8744F21FBFQ38287610-67DDE6D3-8C8F-46F8-8CB2-3AB7C5ED5343Q38586748-FA575004-6975-4949-8709-444FA0A96CF0Q40234039-B539DAF7-D040-4B97-B530-188D070C49CCQ41442958-5C15DDF6-A732-434A-BC70-F799E638281FQ42142963-51BBE9DE-A5A0-41E3-96DF-C4CB77D43229Q49483052-07D3E537-6040-4B92-B2A7-DB13BE689CDEQ50895051-C66CCDB2-E08A-4FE4-B12E-789A9DF3C63AQ54379059-8E983E69-093B-4B18-BDAB-F1CCCE0FB434
P2860
Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cost-minimization analysis of ...... nt of Guillain-Barré syndrome.
@ast
Cost-minimization analysis of ...... nt of Guillain-Barré syndrome.
@en
type
label
Cost-minimization analysis of ...... nt of Guillain-Barré syndrome.
@ast
Cost-minimization analysis of ...... nt of Guillain-Barré syndrome.
@en
prefLabel
Cost-minimization analysis of ...... nt of Guillain-Barré syndrome.
@ast
Cost-minimization analysis of ...... nt of Guillain-Barré syndrome.
@en
P2093
P2860
P356
P1476
Cost-minimization analysis of ...... nt of Guillain-Barré syndrome.
@en
P2093
Ashok Chainani
Chester Andrzejewski
David Brown
Elisabeth Hazard
Jeffrey L Winters
P2860
P2888
P356
10.1186/1472-6963-11-101
P577
2011-05-16T00:00:00Z
P5875
P6179
1029866432